Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Egl nine homolog 1 (EGLN1), also widely known as prolyl hydroxylase domain-containing protein 2 (PHD2), is a non-heme iron-containing dioxygenase that serves as the primary cellular oxygen sensor in humans. Under normoxic conditions, EGLN1/PHD2 utilizes oxygen and 2-oxoglutarate as co-substrates to hydroxylate specific proline residues on the alpha subunits of hypoxia-inducible factors (HIF-1α and HIF-2α). This post-translational modification targets HIF-α for ubiquitination by the von Hippel-Lindau (VHL) E3 ligase complex and subsequent proteasomal degradation. In hypoxia, the enzyme's activity is suppressed, allowing HIF-α to accumulate, translocate to the nucleus, and activate transcription of genes regulating erythropoiesis, angiogenesis, and anaerobic metabolism. Small-molecule inhibitors of EGLN1/PHD2, such as roxadustat, daprodustat, and vadadustat, mimic hypoxia by competitively binding to the enzyme's active site. This stabilization of HIF-α stimulates endogenous erythropoietin (EPO) production and improves iron mobilization, making EGLN1/PHD2 a major therapeutic target for anemia associated with chronic kidney disease (CKD).
EGLN1/PHD2 inhibitors act as 2-oxoglutarate (2-OG) mimetics and/or iron chelators that bind to the active site of the enzyme. This competitive inhibition prevents the hydroxylation of proline residues on HIF-1α and HIF-2α, thereby blocking their recognition by the von Hippel-Lindau (VHL) tumor suppressor and subsequent proteasomal degradation. The resulting stabilization and nuclear translocation of HIF-α subunits lead to the transcriptional activation of target genes, most notably erythropoietin (EPO), which stimulates red blood cell production.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Egl nine homolog 1 (EGLN1).